IRX1 and breast cancer: miR-646 targets the TET1 3′-UTR and decreases its expression, promoting the down-regulation of Iroquois Homeobox 1 (IRX1) expression via methylation of its promoter in MCF-7 and MDA-MB-231 BC cells and in vivo.